175 related articles for article (PubMed ID: 36920744)
1. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM; Scarisbrick JJ; Dummer R; Whittaker S; Duvic M; Kim YH; Quaglino P; Zinzani PL; Bechter O; Eradat H; Pinter-Brown L; Akilov OE; Geskin L; Sanches JA; Ortiz-Romero PL; Weichenthal M; Fisher DC; Walewski J; Trotman J; Taylor K; Dalle S; Stadler R; Lisano J; Bunn V; Little M; Prince HM
Blood Adv; 2021 Dec; 5(23):5098-5106. PubMed ID: 34507350
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.
Podkonjak T; Cranmer H; Scarisbrick J; McCarthy G; Lilley C; Cheng LI
J Comp Eff Res; 2022 Feb; 11(3):193-202. PubMed ID: 34879742
[No Abstract] [Full Text] [Related]
5. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM; Kim YH; Horwitz SM; Dummer R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Trotman J; Taylor K; Dalle S; Weichenthal M; Walewski J; Fisher D; Dréno B; Stadler R; Feldman T; Kuzel TM; Wang Y; Palanca-Wessels MC; Zagadailov E; Trepicchio WL; Zhang W; Lin HM; Liu Y; Huebner D; Little M; Whittaker S; Duvic M;
Lancet; 2017 Aug; 390(10094):555-566. PubMed ID: 28600132
[TBL] [Abstract][Full Text] [Related]
6. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Fleeman N; Houten R; Chaplin M; Boland A; Beale S; Dundar Y; McEntee J; Syndikus I
Pharmacoecon Open; 2020 Dec; 4(4):563-574. PubMed ID: 32207075
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
11. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
Parker C; Woods B; Eaton J; Ma E; Selby R; Benson E; Engstrom A; Sajosi P; Briggs A; Bonthapally V
J Med Econ; 2017 Jan; 20(1):8-18. PubMed ID: 27472034
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
Liu J; Zheng L; Chuang LH
J Med Econ; 2022; 25(1):99-107. PubMed ID: 34927526
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
Muniesa C; Gallardo F; García-Doval I; Estrach MT; Combalia A; Morillo-Andújar M; De la Cruz-Vicente F; Machan S; Moya-Martínez C; Rovira R; Sanchez-Gonzalez B; Acebo E; Amutio E; Peñate Y; Losada-Castillo MDC; García-Muret MP; Iznardo H; Román-Curto C; Cañueto J; Fernández-de-Misa R; Flórez Á; Izu RM; Torres-Navarro I; Zayas A; Pérez-Paredes G; Blanes M; Yanguas JI; Pérez-Ferriols A; Callejas-Charavia M; Ortiz-Romero PL; Pérez-Gil A; Prieto-Torres L; González-Barca E; Servitje O
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):57-64. PubMed ID: 36017748
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
18. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
Hux M; Zou D; Ma E; Sajosi P; Engstrom A; Selby R; Benson E; Briggs A; Bonthapally V
J Health Econ Outcomes Res; 2017; 4(2):188-203. PubMed ID: 37661948
[No Abstract] [Full Text] [Related]
19. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.
Lewis DJ; Talpur R; Huen AO; Tetzlaff MT; Duvic M
JAMA Dermatol; 2017 Dec; 153(12):1302-1306. PubMed ID: 28980004
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
